Tearsheet
RGNX Home Investment Highlights Valuation, Metrics & Events Price Chart Why The Stock Moved Return vs. Risk About RGNX Interactive Breakdown Better Bets vs. RGNX Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Forward Guidance Insider Activity Trade Sentinel Industry Resource Links External Quote Links

Regenxbio (RGNX)

Market Price (5/4/2026): $9.13 | Market Cap: $472.5 Mil
Sector: Health Care | Industry: Biotechnology

Regenxbio (RGNX)

Market Price (5/4/2026): $9.13
Market Cap: $472.5 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -33%

Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 105%

Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more.

Weak multi-year price returns
2Y Excs Rtn is -85%, 3Y Excs Rtn is -129%

Meaningful short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 12.63, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -161 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -95%

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 20%

Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -73%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -74%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -45%

Key risks
RGNX key risks include [1] heavy dependence on the successful clinical and regulatory outcomes for its pivotal programs, Show more.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -33%
1 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 105%
2 Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more.
3 Weak multi-year price returns
2Y Excs Rtn is -85%, 3Y Excs Rtn is -129%
4 Meaningful short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 12.63, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13%
5 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -161 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -95%
6 Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 20%
7 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -73%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -74%
8 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -45%
9 Key risks
RGNX key risks include [1] heavy dependence on the successful clinical and regulatory outcomes for its pivotal programs, Show more.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Regenxbio (RGNX) stock has lost about 20% since 1/31/2026 because of the following key factors:

1. FDA clinical holds on gene therapy programs significantly impacted investor confidence.

On January 28, 2026, Regenxbio announced that the U.S. Food and Drug Administration (FDA) placed clinical holds on its RGX-111 and RGX-121 gene therapy programs. This decision followed the identification of a brain tumor in a patient participating in a Phase 1/2 trial for RGX-111, a treatment for Hurler syndrome. The hold was extended to RGX-121 for Hunter syndrome due to similarities in the products and study populations, despite no related cancer cases in RGX-121 trials. This disclosure prompted an immediate 30-35% decline in the company's share price.

2. The FDA issued a Complete Response Letter (CRL) for RGX-121, delaying its potential approval.

Further exacerbating concerns, on February 7, 2026, the FDA issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) of RGX-121 (clemidsogene lanparvovec) for the treatment of Mucopolysaccharidosis II (Hunter syndrome). The CRL cited concerns regarding the adequacy of study eligibility criteria, the comparability of the natural history external control, and the appropriateness of the surrogate endpoint. This news was particularly impactful as RGX-121 had a Prescription Drug User Fee Act (PDUFA) target date of February 8, 2026, for accelerated approval, with the BLA having been accepted in May 2025. This regulatory setback led to a 14.16% drop in RGNX shares on February 9, 2026.

Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -18.3% change in RGNX stock from 1/31/2026 to 5/3/2026 was primarily driven by a -22.6% change in the company's P/S Multiple.
(LTM values as of)13120265032026Change
Stock Price ($)11.169.12-18.3%
Change Contribution By: 
Total Revenues ($ Mil)1611705.7%
P/S Multiple3.62.8-22.6%
Shares Outstanding (Mil)5252-0.1%
Cumulative Contribution-18.3%

LTM = Last Twelve Months as of date shown

Market Drivers

1/31/2026 to 5/3/2026
ReturnCorrelation
RGNX-18.3% 
Market (SPY)3.6%48.3%
Sector (XLV)-5.8%46.8%

Fundamental Drivers

The -28.6% change in RGNX stock from 10/31/2025 to 5/3/2026 was primarily driven by a -34.4% change in the company's P/S Multiple.
(LTM values as of)103120255032026Change
Stock Price ($)12.779.12-28.6%
Change Contribution By: 
Total Revenues ($ Mil)1561709.4%
P/S Multiple4.22.8-34.4%
Shares Outstanding (Mil)5152-0.5%
Cumulative Contribution-28.6%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 5/3/2026
ReturnCorrelation
RGNX-28.6% 
Market (SPY)5.5%34.2%
Sector (XLV)1.5%47.6%

Fundamental Drivers

The -5.1% change in RGNX stock from 4/30/2025 to 5/3/2026 was primarily driven by a -52.8% change in the company's P/S Multiple.
(LTM values as of)43020255032026Change
Stock Price ($)9.619.12-5.1%
Change Contribution By: 
Total Revenues ($ Mil)83170104.5%
P/S Multiple5.92.8-52.8%
Shares Outstanding (Mil)5152-1.7%
Cumulative Contribution-5.1%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2025 to 5/3/2026
ReturnCorrelation
RGNX-5.1% 
Market (SPY)30.4%39.4%
Sector (XLV)5.2%37.4%

Fundamental Drivers

The -52.9% change in RGNX stock from 4/30/2023 to 5/3/2026 was primarily driven by a -62.8% change in the company's P/S Multiple.
(LTM values as of)43020235032026Change
Stock Price ($)19.369.12-52.9%
Change Contribution By: 
Total Revenues ($ Mil)11317051.2%
P/S Multiple7.42.8-62.8%
Shares Outstanding (Mil)4352-16.3%
Cumulative Contribution-52.9%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2023 to 5/3/2026
ReturnCorrelation
RGNX-52.9% 
Market (SPY)78.7%33.6%
Sector (XLV)14.3%33.2%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
RGNX Return-28%-31%-21%-57%86%-38%-80%
Peers Return-31%18%-2%19%-23%-7%-32%
S&P 500 Return27%-19%24%23%16%5%92%

Monthly Win Rates [3]
RGNX Win Rate42%33%33%33%75%25% 
Peers Win Rate40%65%42%45%47%35% 
S&P 500 Win Rate75%42%67%75%67%50% 

Max Drawdowns [4]
RGNX Max Drawdown-36%-41%-43%-60%-31%-46% 
Peers Max Drawdown-42%-30%-35%-30%-51%-24% 
S&P 500 Max Drawdown-1%-25%-1%-2%-15%-7% 

[1] Cumulative total returns since the beginning of 2021
[2] Peers: SRPT, BMRN, VRTX, QURE, RCKT. See RGNX Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/1/2026 (YTD)

How Low Can It Go

EventRGNXS&P 500
2025 US Tariff Shock
  % Loss-28.8%-18.8%
  % Gain to Breakeven40.5%23.1%
  Time to Breakeven14 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-27.3%-9.5%
  % Gain to Breakeven37.5%10.5%
  Time to Breakeven10 days24 days
2023 SVB Regional Banking Crisis
  % Loss-22.7%-6.7%
  % Gain to Breakeven29.4%7.1%
  Time to Breakeven279 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-43.6%-24.5%
  % Gain to Breakeven77.3%32.4%
  Time to Breakeven72 days427 days
2015-2016 China Devaluation / Global Growth Scare
  % Loss-61.8%-12.2%
  % Gain to Breakeven162.0%13.9%
  Time to Breakeven556 days62 days
2014-2016 Oil Price Collapse
  % Loss-60.4%-6.8%
  % Gain to Breakeven152.3%7.3%
  Time to Breakeven592 days15 days

Compare to SRPT, BMRN, VRTX, QURE, RCKT

In The Past

Regenxbio's stock fell -28.8% during the 2025 US Tariff Shock. Such a loss loss requires a 40.5% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventRGNXS&P 500
2025 US Tariff Shock
  % Loss-28.8%-18.8%
  % Gain to Breakeven40.5%23.1%
  Time to Breakeven14 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-27.3%-9.5%
  % Gain to Breakeven37.5%10.5%
  Time to Breakeven10 days24 days
2023 SVB Regional Banking Crisis
  % Loss-22.7%-6.7%
  % Gain to Breakeven29.4%7.1%
  Time to Breakeven279 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-43.6%-24.5%
  % Gain to Breakeven77.3%32.4%
  Time to Breakeven72 days427 days
2015-2016 China Devaluation / Global Growth Scare
  % Loss-61.8%-12.2%
  % Gain to Breakeven162.0%13.9%
  Time to Breakeven556 days62 days
2014-2016 Oil Price Collapse
  % Loss-60.4%-6.8%
  % Gain to Breakeven152.3%7.3%
  Time to Breakeven592 days15 days

Compare to SRPT, BMRN, VRTX, QURE, RCKT

In The Past

Regenxbio's stock fell -28.8% during the 2025 US Tariff Shock. Such a loss loss requires a 40.5% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Regenxbio (RGNX)

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

AI Analysis | Feedback

Moderna for gene therapy: Like Moderna uses its mRNA platform to develop vaccines and therapies, Regenxbio uses its proprietary NAV technology platform to deliver genes for treating various diseases.

CRISPR Therapeutics, but for gene delivery: Similar to how CRISPR Therapeutics focuses on gene editing to treat genetic diseases, Regenxbio specializes in gene delivery using its AAV platform to introduce therapeutic genes into cells.

AI Analysis | Feedback

REGENXBIO (RGNX) offers the following major products and services:

  • RGX-314: A gene therapy candidate in Phase III clinical trial for the treatment of wet age-related macular degeneration.
  • RGX-121: A gene therapy candidate in Phase I/II clinical trial to treat mucopolysaccharidosis type II.
  • RGX-111: A gene therapy candidate in Phase I/II clinical trial for treating mucopolysaccharidosis type I.
  • RGX-181: A preclinical gene therapy candidate for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease.
  • RGX-202: A gene therapy candidate in Phase I/II clinical trial to treat Duchenne muscular dystrophy.
  • RGX-381: A preclinical gene therapy candidate to treat the ocular manifestations of CLN2 disease.
  • NAV Technology Platform Licensing: Licensing its proprietary adeno-associated virus gene delivery platform to other biotechnology and pharmaceutical companies, including collaborations for novel gene therapies.

AI Analysis | Feedback

Regenxbio (RGNX) is a clinical-stage biotechnology company. As such, it does not currently sell finished pharmaceutical products directly to individuals (patients).

Based on the provided description, its major customers are other companies that license its proprietary technology platform or collaborate on the development of gene therapies.

The primary category of customers for Regenxbio is:

  • Other biotechnology and pharmaceutical companies: These companies license Regenxbio's NAV Technology Platform for their own product development.

One specific customer company mentioned in the description is:

  • Neurimmune AG (private company)

AI Analysis | Feedback

  • Catalent, Inc. (CTLT)

AI Analysis | Feedback

Curran M. Simpson, President and Chief Executive Officer, Board Member

Curran M. Simpson was appointed President and Chief Executive Officer of REGENXBIO, effective July 1, 2024. He previously served as the company's Chief Operating Officer since January 2023, overseeing Research & Clinical Development, Corporate Strategy, Manufacturing & Quality, Regulatory, and Commercial Operations. Mr. Simpson joined REGENXBIO in 2015, initially as Chief Technology and Operations Officer. Before REGENXBIO, he was the Regional Supply Chain Head for North America and Interim Chief Operating Officer at GlaxoSmithKline (GSK). He also served as interim CEO at Human Genome Sciences (HGS), where he led its integration into GSK, and held senior operational roles at HGS. Earlier in his career, Mr. Simpson was Director of Manufacturing Sciences at Biogen and held development and engineering roles at Genentech, working on products such as Herceptin® and Avastin®.

Mitchell Chan, Executive Vice President and Chief Financial Officer, Treasurer and Principal Accounting Officer

Mitchell Chan was appointed Executive Vice President and Chief Financial Officer of REGENXBIO, effective September 17, 2024, bringing nearly two decades of biopharmaceutical financial leadership experience. Most recently, he served as Operating Partner at Catalio Capital Management, LP, a venture capital firm, where he acted as CFO for several portfolio companies and provided investment advice. From 2018 to 2021, Mr. Chan was the Chief Financial Officer of Viela Bio, Inc., overseeing a successful IPO and the company's $3.1 billion acquisition by Horizon Therapeutics plc. Prior to Viela, he held various financial and investor relations leadership roles at AstraZeneca and Genentech-Roche. He has served on the Board of Directors of Avalo Therapeutics since 2021.

Kenneth T. Mills, Chairman of the Board

Kenneth T. Mills co-founded REGENXBIO Inc. in 2009 and served as its President and Chief Executive Officer from inception until July 2024, when he transitioned to Chairman of the Board. He led REGENXBIO's initial public offering on Nasdaq in 2015. Prior to co-founding REGENXBIO, Mr. Mills was the Chief Financial Officer and Vice President of Business Development at Meso Scale Diagnostics, a privately held life sciences company, where he was part of the original management team and helped establish operations and financing strategies. From 1997 to 2003, he was Director of Business Development at IGEN International, a medical diagnostics firm, until its acquisition by Roche Diagnostics. Between 2007 and 2015, Mr. Mills was a partner at FoxKiser, a life sciences consulting firm. He currently also serves as President, Chief Executive Officer, and director of Tagworks Pharmaceuticals BV.

Patrick J. Christmas II, J.D., Executive Vice President, Chief Strategy Officer and Chief Legal Officer

Patrick J. Christmas II has over 15 years of leadership experience in life sciences and public markets. Before joining REGENXBIO, he was Vice President, General Counsel and Secretary at Lumara Health (formerly KV Pharmaceutical Company) through its acquisition by AMAG Pharmaceuticals and Perrigo. Prior to Lumara Health, Mr. Christmas was General Counsel and Secretary at the Wellstat Group of Companies and General Counsel at BioVeris Corporation until its acquisition by Roche.

Ram Palanki, Pharm.D., Executive Vice President & Chief Commercial Officer

Ram Palanki has nearly 20 years of experience in the development and commercialization of biopharmaceuticals and medical devices. Before joining REGENXBIO, Dr. Palanki was Senior Vice President of Commercial for the Americas at Santen Inc. Previously, he served as an executive team member leading the strategy and operations for the pre-launch and global commercialization of a first-in-class biologic at ThromboGenics. He has held roles of increasing responsibility at several companies, including the launch of LUCENTIS® at Genentech. Dr. Palanki is also the founder and a Director of Revopsis Therapeutics, Inc. He also served as an Independent Director at Hyperion DeFi, Inc. from 2022 to 2025.

AI Analysis | Feedback

The key risks to Regenxbio's business are as follows:
  1. Clinical Trial Failures and Regulatory Approval Risk: As a clinical-stage biotechnology company, Regenxbio's success is heavily dependent on the successful outcome of its clinical trials and the subsequent ability to obtain regulatory approval for its gene therapy product candidates. The lead product candidate, RGX-314, is in Phase III, while several others are in earlier Phase I/II or preclinical stages. Failure of any of these candidates in clinical trials due to lack of efficacy, safety concerns, or inability to secure regulatory approval would significantly impact the company's prospects and financial performance.
  2. Reliance on NAV Technology Platform: Regenxbio's entire pipeline and licensing strategy are based on its proprietary NAV Technology Platform, an adeno-associated virus gene delivery platform. Any unforeseen issues, limitations, or long-term safety concerns specific to the NAV Technology Platform itself could adversely affect all its product candidates and the viability of its business model.
  3. Intellectual Property Protection: Regenxbio's business model relies on its proprietary NAV Technology Platform and product candidates. The company's ability to protect its intellectual property rights, including patents and trade secrets, is crucial. Challenges to or invalidation of its patents, or the inability to obtain new patent protection, could diminish its competitive advantage and impact its licensing revenue.

AI Analysis | Feedback

null

AI Analysis | Feedback

Regenxbio (RGNX) is a clinical-stage biotechnology company focused on gene therapy. The addressable markets for its main product candidates are as follows:

RGX-314 for Wet Age-Related Macular Degeneration (Wet AMD)

  • The global wet age-related macular degeneration (AMD) market was valued at USD 10.6 billion in 2025 and is projected to reach USD 16.7 billion by 2032.
  • Another estimate places the global market at USD 10.82 billion in 2023, expected to grow to USD 17.99 billion by 2030.
  • Across the top 7 markets (U.S., EU4, U.K., and Japan), the wet AMD market reached approximately USD 9,528.8 million in 2024 and is anticipated to grow to USD 18,317.5 million by 2035.
  • In the United States, the market size for Wet AMD was approximately USD 2,599 million in 2023, with projections for continued growth at a Compound Annual Growth Rate (CAGR) of 6.6% by 2034.

RGX-121 for Mucopolysaccharidosis Type II (MPS II / Hunter Syndrome)

  • Hunter Syndrome is an ultra-rare genetic disorder, affecting roughly 1 in 100,000 to 170,000 births.
  • There are approximately 800 to 900 target patients in the U.S. and Europe for RGX-121.
  • The global mucopolysaccharidosis (MPS) type II segment is projected to generate USD 236.9 million in revenue by 2025.
  • The U.S. accounted for the largest Hunter Syndrome market size among the 7MM (U.S., EU4, U.K., and Japan) countries in 2025.

RGX-111 for Mucopolysaccharidosis Type I (MPS I / Hurler Syndrome)

  • MPS I is a rare genetic disease, estimated to occur in 1 in 100,000 births.
  • The market size for Mucopolysaccharidosis Type I in the 7MM (U.S., EU4, U.K., and Japan) was USD 145 million in 2024, with an expectation to grow to USD 297 million by 2034.
  • In the U.S., the MPS I market was approximately USD 70 million in 2024, representing 48% of the total 7MM market.
  • Globally, the mucopolysaccharidosis type I market was valued at US$ 625 million in 2022 and is expected to reach US$ 1,288 million by 2031.

RGX-202 for Duchenne Muscular Dystrophy (DMD)

  • The global Duchenne muscular dystrophy (DMD) drug market was valued at USD 3.47 billion in 2023 and is projected to reach USD 9.91 billion by 2030.
  • Another report states the global DMD treatment market is estimated to grow from US$ 4.3 billion in 2026 to US$ 13.8 billion by 2033.
  • The global DMD therapeutics market size reached US$ 2.19 billion in 2024 and is expected to reach US$ 6.64 billion by 2033.
  • The global Duchenne muscular dystrophy treatment market is projected to reach USD 19.18 billion by 2034.
  • In the U.S., annual revenue for RGX-202 is expected to reach $163 million by 2039. North America held the largest revenue share of the global DMD drugs market in 2023, at 45.0%.

AI Analysis | Feedback

REGENXBIO Inc. (RGNX) is positioned for future revenue growth over the next two to three years, driven primarily by the advancement and potential commercialization of its lead gene therapy candidates, along with ongoing revenue from its proprietary technology platform.

Here are 3-5 expected drivers of future revenue growth for Regenxbio:

  1. Commercialization of RGX-314 (sura-vec) for Wet Age-Related Macular Degeneration (AMD): REGENXBIO anticipates top-line data from its pivotal ATMOSPHERE and ASCENT trials for RGX-314 in wet AMD in the fourth quarter of 2026. If approved, RGX-314 would represent a significant new product launch, as it is positioned to be the first gene therapy for wet AMD, potentially generating substantial product revenue in late 2027 or 2028. The development of sura-vec is also part of a collaboration with AbbVie, indicating strong commercial backing.
  2. Launch of RGX-202 for Duchenne Muscular Dystrophy (DMD): REGENXBIO expects to release pivotal topline data for RGX-202 in early Q2 2026 and plans to submit a Biologics License Application (BLA) under the accelerated approval pathway in mid-2026. This accelerated pathway could lead to an earlier market entry, potentially bringing product revenue from late 2026 or 2027.
  3. Milestone Payments from Strategic Collaborations: A notable near-term driver is the expected $100 million milestone payment from AbbVie upon the first patient dosing in the NAVIGATE pivotal study for diabetic retinopathy, which is anticipated in the first half of 2026. Further milestone payments could materialize from other existing or new collaborations as pipeline candidates advance.
  4. Continued Royalty Revenue from NAV Technology Platform Licensees: REGENXBIO currently earns royalty revenue from the sales of products, such as Zolgensma and Evrysdi, that utilize its proprietary NAV Technology Platform. The company also entered into a royalty monetization agreement for up to $250 million, securing $150 million at closing in May 2025, with an additional $50 million potentially funded by April 2027 upon achievement of Zolgensma sales milestones. This ongoing and potentially increasing royalty stream provides a stable, non-dilutive revenue component.

AI Analysis | Feedback

Share Issuance

  • REGENXBIO priced an underwritten public offering of common stock and pre-funded warrants in March 2024, expecting gross proceeds of approximately $140.0 million.
  • In January 2021, the company announced its intent to offer and sell $175.0 million of its common stock in an underwritten public offering.
  • As of March 2026, REGENXBIO has an active $300 million shelf registration and a $150 million At-The-Market (ATM) facility that could lead to future share issuances.

Inbound Investments

  • In March 2025, REGENXBIO received a non-dilutive $110.0 million upfront payment from Nippon Shinyaku as part of their partnership for the RGX-121 program.
  • The company closed a non-dilutive, limited recourse royalty bond agreement of up to $250 million with Healthcare Royalty (HCRx) in May 2025, receiving $150 million at closing, with an additional $50 million expected by April 30, 2027, upon ZOLGENSMA sales milestones.
  • REGENXBIO anticipates a $100 million milestone payment from AbbVie upon the first patient dosed in the Phase IIb portion of the NAAVIGATE study for diabetic retinopathy, expected in Q2 2026.

Capital Expenditures

  • Capital expenditures for the last 12 months prior to March 2026 were -$2.41 million.
  • Research and development expenses, which include manufacturing-related expenses, increased in 2025 to $228.3 million, up from $208.5 million in 2024, primarily for RGX-202 pivotal trials, Sura-vec, and RGX-121.
  • The company continues to manufacture RGX-202 for commercial supply at its in-house Manufacturing Innovation Center.

Better Bets vs. Regenxbio (RGNX)

Latest Trefis Analyses

TitleDate
0DASHBOARDS 
1Regenxbio Stock Pre-Market (-18%): FDA Rejects Key Drug RGX-12102/10/2026
2Regenxbio Earnings Notes12/16/2025
3Would You Still Hold Regenxbio Stock If It Fell 30%?10/17/2025
4Day 5 of Loss Streak for REGENXBIO Stock with -19% Return (vs. -43% YTD) [10/31/2023]10/31/2023
5REGENXBIO (RGNX) Stock Has 57% Chance Of Rise In The Next One Month02/13/2023
6REGENXBIO (RGNX) Stock Has 49% Chance Of Rise In The Next One Month12/04/2022
7[11/3/2022] REGENXBIO (RGNX) Shares Moved -13% Today  (Extremely rare event)11/03/2022
8Dates Cached For RGNX10/21/2022
9REGENXBIO (RGNX) Stock Has 71% Chance Of Rise In The Next One Month09/14/2022
10Regenxbio vs. Out Of Favor Health Care Stocks: Which Is A Better Investment?07/07/2022
11ARTICLES 
12What’s Next For REGENXBIO Stock After A 20% Fall Yesterday?10/05/2021

Trade Ideas

Select ideas related to RGNX.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
GEHC_4302026_Dip_Buyer_FCFYield04302026GEHCGE HealthCare TechnologiesDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		0.0%0.0%0.0%
IQV_4302026_Dip_Buyer_FCFYield04302026IQVIQVIADip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		0.0%0.0%0.0%
UHS_4302026_Dip_Buyer_FCFYield04302026UHSUniversal Health ServicesDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		0.0%0.0%0.0%
ABT_4302026_Dip_Buyer_ValueBuy04302026ABTAbbott LaboratoriesDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		0.0%0.0%0.0%
ZBIO_4302026_Insider_Buying_45D_2Buy_200K04302026ZBIOZenas BioPharmaInsiderInsider Buys 45DStrong Insider Buying
Companies with multiple insider buys in the last 45 days		0.0%0.0%0.0%

Recent Active Movers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Peers to compare with:

Financials

RGNXSRPTBMRNVRTXQURERCKTMedian
NameRegenxbioSarepta .BioMarin.Vertex P.uniQure Rocket P. 
Mkt Price9.1221.4954.06423.9219.133.5620.31
Mkt Cap0.52.310.4107.51.20.41.7
Rev LTM1702,1983,22112,0011601,184
Op Inc LTM-161-6584094,554-181-229-171
FCF LTM-126-3157173,194-178-191-152
FCF 3Y Avg-177-4194151,832-175-206-176
CFO LTM-124-2058283,631-178-190-151
CFO 3Y Avg-172-3045202,225-169-198-170

Growth & Margins

RGNXSRPTBMRNVRTXQURERCKTMedian
NameRegenxbioSarepta .BioMarin.Vertex P.uniQure Rocket P. 
Rev Chg LTM104.5%15.6%12.9%8.9%-40.6%-12.9%
Rev Chg 3Y Avg25.6%33.9%15.4%10.4%-18.2%-15.4%
Rev Chg Q43.0%-32.7%17.0%9.5%6.6%-9.5%
QoQ Delta Rev Chg LTM5.7%-8.9%4.1%2.4%2.2%-2.4%
Op Inc Chg LTM30.3%-401.6%-13.7%2,051.3%0.4%16.4%8.4%
Op Inc Chg 3Y Avg14.0%-56.7%130.7%644.7%-20.0%-1.6%6.2%
Op Mgn LTM-94.6%-29.9%12.7%37.9%-1,125.9%--29.9%
Op Mgn 3Y Avg-223.1%-13.3%12.9%24.7%-1,193.2%--13.3%
QoQ Delta Op Mgn LTM1.5%-26.4%-7.2%38.7%-23.8%--7.2%
CFO/Rev LTM-72.7%-9.3%25.7%30.3%-1,105.5%--9.3%
CFO/Rev 3Y Avg-174.2%-20.2%17.5%20.5%-900.1%--20.2%
FCF/Rev LTM-74.1%-14.3%22.3%26.6%-1,108.6%--14.3%
FCF/Rev 3Y Avg-179.3%-26.7%13.7%17.0%-930.6%--26.7%

Valuation

RGNXSRPTBMRNVRTXQURERCKTMedian
NameRegenxbioSarepta .BioMarin.Vertex P.uniQure Rocket P. 
Mkt Cap0.52.310.4107.51.20.41.7
P/S2.81.03.29.074.1-3.2
P/Op Inc-2.9-3.425.423.6-6.6-1.7-2.3
P/EBIT-3.2-3.421.123.1-9.1-1.8-2.5
P/E-2.4-3.229.827.2-6.0-1.8-2.1
P/CFO-3.8-11.012.629.6-6.7-2.1-3.0
Total Yield-41.1%-31.7%3.4%3.7%-16.7%-56.1%-24.2%
Dividend Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg-30.2%-7.6%3.5%1.7%-27.3%-24.6%-16.1%
D/E0.20.50.10.00.10.10.1
Net D/E-0.30.0-0.1-0.0-0.5-0.4-0.2

Returns

RGNXSRPTBMRNVRTXQURERCKTMedian
NameRegenxbioSarepta .BioMarin.Vertex P.uniQure Rocket P. 
1M Rtn6.9%-7.5%-2.6%-3.4%11.5%0.3%-1.2%
3M Rtn-18.3%5.7%-4.4%-9.8%-15.8%2.3%-7.1%
6M Rtn-28.6%-10.5%0.9%-0.4%-71.7%-5.6%-8.0%
12M Rtn-12.3%-66.2%-12.8%-15.4%29.5%-55.6%-14.1%
3Y Rtn-54.2%-83.5%-43.4%22.3%-9.6%-81.0%-48.8%
1M Excs Rtn-4.3%-12.9%-15.5%-15.2%3.3%-11.6%-12.2%
3M Excs Rtn-22.5%1.5%-8.6%-14.0%-20.0%-1.9%-11.3%
6M Excs Rtn-33.9%-13.3%-0.7%-3.3%-77.8%-10.7%-12.0%
12M Excs Rtn-34.9%-95.4%-44.9%-46.6%-0.2%-83.2%-45.8%
3Y Excs Rtn-128.7%-160.7%-120.1%-47.1%-79.3%-157.9%-124.4%

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Development and commercialization of gene therapies to treat an array of diseases8390113470155
Total8390113470155


Net Income by Segment
$ Mil20252024202320222021
Development and commercialization of gene therapies to treat an array of diseases-227-263   
Total-227-263   


Price Behavior

Price Behavior
Market Price$9.12 
Market Cap ($ Bil)0.5 
First Trading Date09/17/2015 
Distance from 52W High-42.9% 
   50 Days200 Days
DMA Price$8.76$10.53
DMA Trendindeterminatedown
Distance from DMA4.1%-13.4%
 3M1YR
Volatility75.6%81.4%
Downside Capture2.252.01
Upside Capture219.72255.03
Correlation (SPY)46.4%39.0%
RGNX Betas & Captures as of 4/30/2026

 1M2M3M6M1Y3Y
Beta1.922.732.321.922.561.63
Up Beta1.661.481.843.022.171.59
Down Beta5.020.510.88-0.411.290.91
Up Capture152%388%255%190%614%569%
Bmk +ve Days15223166141428
Stock +ve Days11192858120351
Down Capture710%360%284%213%200%113%
Bmk -ve Days4183056108321
Stock -ve Days10233566129393

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with RGNX
RGNX-3.0%81.5%0.32-
Sector ETF (XLV)5.2%16.0%0.1337.3%
Equity (SPY)30.6%12.5%1.8839.3%
Gold (GLD)39.5%27.2%1.207.9%
Commodities (DBC)51.5%17.9%2.20-7.0%
Real Estate (VNQ)13.1%13.5%0.6718.9%
Bitcoin (BTCUSD)-17.1%42.2%-0.3322.8%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with RGNX
RGNX-23.5%69.2%-0.10-
Sector ETF (XLV)5.0%14.6%0.1732.9%
Equity (SPY)12.8%17.1%0.5936.5%
Gold (GLD)20.5%17.9%0.949.8%
Commodities (DBC)14.3%19.1%0.613.9%
Real Estate (VNQ)3.5%18.8%0.0930.6%
Bitcoin (BTCUSD)7.7%56.2%0.3518.1%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with RGNX
RGNX-1.9%67.7%0.27-
Sector ETF (XLV)9.1%16.5%0.4536.2%
Equity (SPY)14.9%17.9%0.7138.6%
Gold (GLD)13.6%15.9%0.715.1%
Commodities (DBC)9.7%17.7%0.4611.5%
Real Estate (VNQ)5.7%20.7%0.2428.7%
Bitcoin (BTCUSD)67.7%66.9%1.0712.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date4152026
Short Interest: Shares Quantity6.9 Mil
Short Interest: % Change Since 33120263.5%
Average Daily Volume0.5 Mil
Days-to-Cover Short Interest12.6 days
Basic Shares Quantity51.8 Mil
Short % of Basic Shares13.4%

Returns Analyses

Earnings Returns History

Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
3/5/2026-4.6%2.6%-6.7%
11/6/2025-3.8%-0.1%14.0%
8/7/2025-4.0%8.5%18.0%
3/13/20252.6%27.6%-10.1%
11/6/202418.7%13.1%1.6%
8/1/2024-2.0%-10.7%-8.2%
5/8/2024-5.9%-2.6%-15.5%
2/27/2024-0.6%22.9%10.8%
...
SUMMARY STATS   
# Positive7119
# Negative13911
Median Positive3.1%10.3%14.0%
Median Negative-4.0%-4.5%-11.7%
Max Positive18.7%27.6%25.0%
Max Negative-13.2%-15.6%-20.9%

SEC Filings

Expand for More
Report DateFiling DateFiling
12/31/202503/05/202610-K
09/30/202511/06/202510-Q
06/30/202508/07/202510-Q
03/31/202505/12/202510-Q
12/31/202403/13/202510-K
09/30/202411/06/202410-Q
06/30/202408/01/202410-Q
03/31/202405/08/202410-Q
12/31/202302/27/202410-K
09/30/202311/08/202310-Q
06/30/202308/02/202310-Q
03/31/202305/03/202310-Q
12/31/202202/28/202310-K
09/30/202211/03/202210-Q
06/30/202208/03/202210-Q
03/31/202205/04/202210-Q

Recent Forward Guidance [BETA]

Latest: Q4 2025 Earnings Reported 3/5/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
Q2 2026 Milestone Payment 100.00 Mil    
2027 Cash Runway      

Prior: Q3 2025 Earnings Reported 11/6/2025

null

Insider Activity

Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value		Value of
Held Shares		Form
1Pakola, SteveChief Medical OfficerDirectSell312202610.355,12453,0332,566,034Form
2Simpson, CurranChief Executive OfficerDirectSell1010202512.6220,811262,6352,727,964Form
3Simpson, CurranChief Executive OfficerDirectSell1001202510.037,62476,4692,376,839Form
4Simpson, CurranChief Executive OfficerDirectSell912202510.027,73477,4952,450,862Form
5Mills, Kenneth TDirectSell51420257.9120,602163,0463,760,013Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.